Some patients, such as those with IIb or stage III melanoma, are at high risk for the development of recurrence after treatment.
Although these patients are clinically free of disease after undergoing primary treatment, they are more likely to have some microscopic disease in the body that studies have not yet been able to identify.
Adjuvant therapy (auxiliary drug treatment used to make possibility of relapse less for those at high risk) is also considered.
Hemorrhoidectomies have a high rate of success; most patients have an uncomplicated recovery with no recurrence of the hemorrhoids.
Modest progress has been made in the treatment of metastatic melanoma over the past decade. With the advent of high dose interleukin-2 (IL-2), it may be possible for a small number of patients to be cured of their disease Despite this, the average median survival in patients treated for metastatic disease may be as short as nine months
The prognosis after the surgical removal of a meningioma generally depends on factors such as the tumor's size, location, and whether it is benign or malignant. Most benign meningiomas have a good prognosis, with high rates of complete surgical resection leading to favorable outcomes and low recurrence rates. However, malignant or atypical meningiomas may have a poorer prognosis and require additional treatments like radiation therapy. Regular follow-up is essential to monitor for any signs of recurrence.
On this basis populations of fair-skinned people living in areas of high sun exposure such as the southwest United States or Australia are subject to increased risk.
On this basis populations of fair-skinned people living in areas of high sun exposure such as the southwest United States or Australia are subject to increased risk.
The risk of recurrence is highest in the first six months after angioplasty, with rates as high as 35% reported in some studies.
Those with recurrence in the same area as the original cancer, or with a single metastatic tumor in the liver or lung, have a chance that surgery will eliminate the disease.
risks are greater with obese patients or those who have had multiple earlier operations or the prior placement of mesh patches. The risk of complications has been shown to be about 13%. The risk of recurrence and repeat surgery is as high as 52%
There is a high risk of tumor recurrence and metastases after transplantation.
Treating the patient who has no evidence of residual disease but who is at high risk for recurrence